Drug Approval | August 23, 2024
Wanbury receives EIR from FDA for Patalganga facility
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Revolutionary technology will further boost OneSource’s scientific services offerings
Subscribe To Our Newsletter & Stay Updated
